CareDx (CDNA) Projected to Post Earnings on Wednesday

CareDx (NASDAQ:CDNA - Get Free Report) will likely be announcing its Q1 2025 earnings results after the market closes on Wednesday, April 30th. Analysts expect CareDx to post earnings of $0.06 per share and revenue of $84.56 million for the quarter.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $1.46. The firm had revenue of $86.58 million during the quarter, compared to analyst estimates of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. On average, analysts expect CareDx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CareDx Stock Performance

NASDAQ:CDNA traded down $0.01 during trading hours on Friday, reaching $18.48. The company's stock had a trading volume of 362,621 shares, compared to its average volume of 851,193. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -6.84 and a beta of 2.18. The firm has a 50-day simple moving average of $19.07 and a 200-day simple moving average of $21.91. CareDx has a 1 year low of $7.42 and a 1 year high of $34.84.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CDNA. The Goldman Sachs Group lowered their target price on CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a report on Wednesday, February 26th. Wells Fargo & Company raised shares of CareDx from an "underweight" rating to an "equal weight" rating and decreased their target price for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. Stephens reissued an "overweight" rating and set a $40.00 price target on shares of CareDx in a research report on Thursday, February 27th. Finally, HC Wainwright decreased their price objective on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $30.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.